Cursiefen C - Search Results

1

[Anti(lymph)angiogenic preconditioning prior to keratoplasty].

Cursiefen C, Regenfuss B, Hos D, Bucher F, Steven P, Heindl LM, Bock F. Cursiefen C, et al. Klin Monbl Augenheilkd. 2013 May;230(5):500-4. doi: 10.1055/s-0032-1328500. Epub 2013 May 21. Klin Monbl Augenheilkd. 2013. PMID: 23695846 Review. German.

2

[Standardized semiquantitative analysis of corneal neovascularization using projected corneal photographs--pilot study after perforating corneal keratoplasty before immune reaction].

Cursiefen C, Wenkel H, Martus P, Langenbucher A, Seitz B, Küchle M. Cursiefen C, et al. Klin Monbl Augenheilkd. 2001 Jul;218(7):484-91. doi: 10.1055/s-2001-16291. Klin Monbl Augenheilkd. 2001. PMID: 11512248 Clinical Trial. German.

3

[Visual rehabilitation and intraocular pressure elevation due to immunological graft rejection following penetrating keratoplasty].

Nguyen NX, Langenbucher A, Cursiefen C, Seitz B, Wenkel H, Küchle M. Nguyen NX, et al. Among authors: cursiefen c. Klin Monbl Augenheilkd. 2001 Jul;218(7):492-7. doi: 10.1055/s-2001-16292. Klin Monbl Augenheilkd. 2001. PMID: 11512249 German.

4

[Immunological graft reactions after penetrating keratoplasty - A prospective randomized trial comparing corneal excimer laser and motor trephination].

Seitz B, Langenbucher A, Diamantis A, Cursiefen C, Küchle M, Naumann GO. Seitz B, et al. Among authors: cursiefen c. Klin Monbl Augenheilkd. 2001 Nov;218(11):710-9. doi: 10.1055/s-2001-18662. Klin Monbl Augenheilkd. 2001. PMID: 11731898 Clinical Trial. German.

5

[Clinical aspects and treatment of immune reactions following penetrating normal-risk keratoplasty].

Nguyen NX, Seitz B, Langenbucher A, Wenkel H, Cursiefen C. Nguyen NX, et al. Among authors: cursiefen c. Klin Monbl Augenheilkd. 2004 Jun;221(6):467-72. doi: 10.1055/s-2004-813282. Klin Monbl Augenheilkd. 2004. PMID: 15236106 Clinical Trial. German.

6

[Inhibition of angiogenesis in the anterior chamber of the eye].

Bock F, König Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C. Bock F, et al. Among authors: cursiefen c. Ophthalmologe. 2007 Apr;104(4):336-44. doi: 10.1007/s00347-007-1512-2. Ophthalmologe. 2007. PMID: 17372736 Review. German.

7

Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.

Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C. Bock F, et al. Among authors: cursiefen c. Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2545-52. doi: 10.1167/iovs.06-0570. Invest Ophthalmol Vis Sci. 2007. PMID: 17525183

8

Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade.

Dietrich T, Onderka J, Bock F, Kruse FE, Vossmeyer D, Stragies R, Zahn G, Cursiefen C. Dietrich T, et al. Among authors: cursiefen c. Am J Pathol. 2007 Jul;171(1):361-72. doi: 10.2353/ajpath.2007.060896. Am J Pathol. 2007. PMID: 17591980 Free PMC article.

9

Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation.

Bock F, Onderka J, Dietrich T, Bachmann B, Pytowski B, Cursiefen C. Bock F, et al. Among authors: cursiefen c. Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):115-9. doi: 10.1007/s00417-007-0683-5. Epub 2007 Oct 2. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 17909835

10

Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

Bock F, König Y, Kruse F, Baier M, Cursiefen C. Bock F, et al. Among authors: cursiefen c. Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):281-4. doi: 10.1007/s00417-007-0684-4. Epub 2007 Oct 13. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 17934753

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

599 results

Search Page

Filters